The transformative power of clinical NGS in oncology testing continues to reveal itself as we dive deeper our NGS DxBook database.

‍

This week, we're spotlighting the correlation between hospital size and the diversity of their NGS panels. Surprisingly, small to mid-sized hospitals are not lagging far behind their larger counterparts (see slide 2 below)!

‍

If you've been following our recent carousels, you'll appreciate that the rapid pace of NGS adoption, driven by both technological advances and reimbursement evolution, is democratizing precision oncology. Whether in the U.S. with its preference for large panels from Illumina, or in Europe where Thermo Fisher's smaller panels have found traction, the underlying narrative is consistent: cancer care is on the cusp of a transformative era in decentralized settings. Institutions, regardless of their size, are embracing the value of diverse panels, underscoring a concerted global move towards more personalized, effective treatments.

‍

As always, feel free to ping Rishikesh with any questions or comments, and swipe for more details!

‍

 #NGSisUnstoppable

‍

‍